Denmark· DK-28105113112
Vipidia
A alogliptin product containing alogliptinbenzoat, registered in Denmark by Takeda Pharma A/S. The same ATC class is registered in 13 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Alogliptin is registered in 13 of 19 countries.
Countries holding a registration under ATC A10BH04 (alogliptin), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 6 of them publish a price we can compare per daily dose
Alogliptin · ATC A10BH04
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Polandprice
- United Kingdom
Price per daily dose
What a daily dose of alogliptin costs, country by country.
Normalised to the WHO defined daily dose (25 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Alogliptin · price per daily dose (25 mg)
USD · FX 28 Sept 2026
- IT Italy$4.54
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Alogliptinbenzoat
- Manufacturer
- Takeda Pharma A/S
- Country
- Denmark (DK)
- ATC code
- A10BH04
- ATC class
- Alogliptin
- Defined daily dose
- 25 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28105113112
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
312 interactions on record for alogliptin.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Alogliptin · interactions on record
312 records
- 3 severe
- 269 moderate
- 40 minor
Most severe, free to view
- GatifloxacinJ01MA16severe
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A10BH04
Alogliptin, as other registers publish it.
- United KingdomAlogliptin 12.5mg tabletsTakeda UK Ltd
- United KingdomAlogliptin 12.5mg tabletsJ M McGill Ltd
- United KingdomAlogliptin 12.5mg tabletsEnnogen Healthcare Ltd
- United KingdomAlogliptin 12.5mg tabletsColorama Pharmaceuticals Ltd
- United KingdomAlogliptin 12.5mg tabletsNiche Pharma Ltd
- United KingdomAlogliptin 25mg tabletsJ M McGill Ltd
- United KingdomAlogliptin 25mg tabletsEnnogen Healthcare Ltd
- United KingdomAlogliptin 25mg tabletsColorama Pharmaceuticals Ltd
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d777c21a-6a54-46fc-a042-a4233b9c93a6 GET /v1/drugs/d777c21a-6a54-46fc-a042-a4233b9c93a6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "filmovertrukne tabletter",
"source": "dkma",
"strength": "25 mg",
"auth_role": "MOD",
"dk_drugid": "28105113112",
"substance": "Alogliptinbenzoat",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "41536"
}See everything about alogliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.